Chemomab Therapeutics Ltd. American Depositary Share(CMMB)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.0B
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -13.40% | 5 |
| Feb | -3.04% | 5 |
| Mar | -12.75% | 6 |
| Apr | -6.38% | 6 |
| May | +9.86% | 6 |
| Jun | -6.95% | 6 |
| Jul | -2.86% | 5 |
| Aug | +4.80% | 5 |
| Sep | -20.77% | 5 |
| Oct | -8.78% | 5 |
| Nov | -4.54% | 5 |
| Dec | -3.45% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.80
SMA 50: $1.71
SMA 200: $2.15
Current: $1.65
EMA 12: $1.77
EMA 26: $1.77
MACD: 0.0027 | Signal: -0.0236
BULLISH
ADX (14): 18.35
RANGE
+DI: 16.02
−DI: 18.12
Momentum Oscillators
RSI (14): 43.83
NEUTRAL
Stoch %K: 12.79
Stoch %D: 22.13
Williams %R: -100.00
Volume & Volatility
BB Upper: $2.08
BB Lower: $1.51
NEUTRAL
OBV: -5,872,561
Vol SMA 20: 43,243
Vol ROC: -10.52%
ATR: $0.15
True Range: $0.20
HV 20: 89.9%
HV 30: 84.2%
HV 60: 70.9%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:30.075000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.79
- Correlation (SPY)
- 30.7%
- R²
- 0.09
- Ann. Volatility
- 71.9%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Insider Activity
Latest: 2026-06-01
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | George Adi Mor | Chief Executive Officer | Mixed | −60,266 | $2.07 | -$20.2K | EDGAR |
| 2023-07-05 | Nissim Darvish | Director | Award (A) | — | — | EDGAR | |
| 2023-06-20 | Jill M. Quigley | Director | Grant (A) | +20,497 opt | — | EDGAR | |
| 2023-06-16 | Sigal Fatal | Chief Financial Officer | Award (A) | — | — | EDGAR | |
| 2023-03-23 | Claude Nicaise | Director | Grant (A) | +25,561 opt | — | EDGAR | |
| 2023-03-23 | Alan Charles Moses | Director | Grant (A) | +25,561 opt | — | EDGAR | |
| 2023-03-23 | Neil Harris Cohen | Director | Award (A) | — | — | EDGAR | |
| 2023-03-23 | Nissim Darvish | Director | Award (A) | — | — | EDGAR | |
| 2023-01-05 | George Adi Mor | Chief Scientific Officer | Sell (S) | −13,800 | $5.03 | -$69.4K | EDGAR |
| 2023-01-05 | OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | Sell (S) | −673,800 | $3.58 | -$2.42M | EDGAR |
| 2022-11-18 | Neil Harris Cohen | Director | Sell (S) | −2,409 | $2.00 | -$4.8K | EDGAR |
| 2022-11-17 | George Adi Mor | Chief Scientific Officer | Sell (S) | −582,023 | $2.08 | -$1.21M | EDGAR |
| 2022-06-21 | Donald Marvin | Executive VP, CFO & COO | Buy (P) | +500 | $3.27 | $1.6K | EDGAR |
| 2022-05-25 | Joel Michael Maryles | Director | Buy (P) | +433 | $2.88 | $1.2K | EDGAR |
| 2022-05-19 | Neil Harris Cohen | Director | Buy (P) | +2,000 | $3.19 | $6.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
11 insiders · @ $1.65
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Israel GP Ltd. | 10%+ Owner | 2,578,174 | $4.25M | $0 | 1 | 2021-03-18 |
| 2 | OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | 2,311,798 | $3.81M | -$2.42M | 1 | 2023-01-05 |
| 3 | PETER THIEL | 10%+ Owner | 1,108,509 | $1.83M | $0 | 1 | 2021-03-18 |
| 4 | George Adi Mor | Chief Executive Officer | 282,859 | $466.7K | -$1.30M | 3 | 2026-06-01 |
| 5 | STEPHEN P SQUINTO | Director | 47,938 | $79.1K | $0 | 1 | 2021-04-21 |
| 6 | Neil Harris Cohen | Director | 10,000 | $16.5K | $142.5K | 8 | 2023-03-23 |
| 7 | Sigal Fatal | Chief Financial Officer | 5,209 | $8.6K | $0 | 2 | 2023-06-16 |
| 8 | Dale R Pfost | Chief Executive Officer | 1,800 | $3.0K | $9.9K | 1 | 2022-03-15 |
| 9 | Donald Marvin | Executive VP, CFO & COO | 1,750 | $2.9K | $6.7K | 2 | 2022-06-21 |
| 10 | Joel Michael Maryles | Director | 1,433 | $2.4K | $5.6K | 4 | 2022-05-25 |
| 11 | Nissim Darvish | Director | 1,200 | $2.0K | $5.1K | 5 | 2023-07-05 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.